324905
Epirubicin Hydrochloride - CAS 56390-09-1 - Calbiochem
A cell-permeable antitumor antibiotic.
别名:
Epirubicin Hydrochloride - CAS 56390-09-1 - Calbiochem, 4ʹ-Epidoxorubicin, HCl
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C27H29NO11 · xHCl
化学文摘社编号:
分子量:
543.52 (free base basis)
UNSPSC Code:
12352200
MDL number:
InChI
1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22-,27-;/m0./s1
InChI key
MWWSFMDVAYGXBV-FGBSZODSSA-N
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic), protect from light
color
orange-red
solubility
water: 1 mg/mL
shipped in
ambient
Quality Level
General description
A cell-permeable, antitumor antibiotic. A stereoisomer of doxorubicin that exhibits reduced cardiotoxicity. Its antitumor actions are mediated by targeting topoisomerase II.
This product has been discontinued.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
Antitumor antibiotic
Antitumor antibiotic
Product does not compete with ATP.
Reversible: no
Preparation Note
Following reconstiution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Luck, H.J., et al. 1996. Semin. Oncol.23, 33.
Sandri, M.I., et al. 1996. Br. J. Cancer73, 1518.
Boddy, A.V., et al. 1995. Eur. J. Cancer31A, 69.
Pouna, P., et al. 1995. Cancer. Chemother. Pharmacol.35, 257.
Sandri, M.I., et al. 1996. Br. J. Cancer73, 1518.
Boddy, A.V., et al. 1995. Eur. J. Cancer31A, 69.
Pouna, P., et al. 1995. Cancer. Chemother. Pharmacol.35, 257.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Harmful & Carcinogenic / Teratogenic (E)
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Carc. 1B - Muta. 1B - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Ramchandra Vigay Amnekar et al.
World journal of gastroenterology, 26(6), 598-613 (2020-02-28)
The prognosis of gastric cancer continues to remain poor, and epigenetic drugs like histone deacetylase inhibitors (HDACi) have been envisaged as potential therapeutic agents. Nevertheless, clinical trials are facing issues with toxicity and efficacy against solid tumors, which may be
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持